Total Payments
$838.46
2024 Payments
$233.72
Companies
22
Transactions
42
Medicare Patients
6,046
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$763.56 (91.1%)
Education$74.90 (8.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $763.56 | 37 | 91.1% |
| Education | $74.90 | 5 | 8.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $161.10 | 6 | $0 (2024) |
| Daiichi Sankyo Inc. | $85.29 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $82.07 | 3 | $0 (2024) |
| GENZYME CORPORATION | $65.82 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $60.08 | 4 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $48.06 | 3 | $0 (2024) |
| Janssen Biotech, Inc. | $48.00 | 2 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $34.39 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $32.59 | 2 | $0 (2024) |
| Celgene Corporation | $25.56 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $233.72 | 12 | Daiichi Sankyo Inc. ($49.23) |
| 2023 | $344.13 | 15 | Astellas Pharma US Inc ($106.00) |
| 2022 | $134.61 | 7 | Janssen Biotech, Inc. ($24.44) |
| 2021 | $53.02 | 3 | GENZYME CORPORATION ($21.00) |
| 2020 | $43.03 | 3 | Novartis Pharmaceuticals Corporation ($17.92) |
| 2019 | $14.78 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($14.78) |
| 2018 | $15.17 | 1 | AbbVie, Inc. ($15.17) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.84 | General |
| 10/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $33.41 | General |
| 03/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 02/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 12/06/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 12/04/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/29/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 05/18/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Oncology | ||||||
| 03/30/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Iron Deficiency Anemia | ||||||
| 02/20/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $17.92 | General |
| Category: ONCOLOGY | ||||||
| 02/09/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.56 | General |
| Category: Hematology | ||||||
| 02/06/2023 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Oncology | ||||||
| 01/30/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Oncology | ||||||
| 01/27/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 1,360 | 45,971 | $1.9M | $630,955 |
| 2022 | 34 | 1,457 | 42,042 | $1.8M | $611,594 |
| 2021 | 44 | 1,692 | 55,364 | $2.3M | $846,259 |
| 2020 | 39 | 1,537 | 40,268 | $1.0M | $366,070 |
Total Patients
6,046
Total Services
183,645
Medicare Billing
$2.5M
Procedure Codes
151
All Medicare Procedures & Services
151 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 10,200 | $1.1M | $425,372 | 37.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 4,140 | $197,110 | $76,922 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 391 | $144,943 | $34,737 | 24.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 63 | 193 | $90,782 | $18,715 | 20.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 16,500 | $36,900 | $14,408 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 52 | 89 | $46,271 | $11,821 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $19,028 | $4,556 | 23.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 127 | 432 | $13,686 | $4,324 | 31.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 49 | 94 | $20,990 | $4,285 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 63 | $16,604 | $4,134 | 24.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 139 | 506 | $11,795 | $3,742 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $14,027 | $3,553 | 25.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 68 | $24,908 | $3,056 | 12.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 47 | 133 | $14,337 | $2,843 | 19.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 106 | 299 | $6,948 | $2,456 | 35.3% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 14 | 45 | $7,353 | $1,940 | 26.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 41 | 157 | $15,370 | $1,755 | 11.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 83 | $12,326 | $1,559 | 12.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 134 | $9,876 | $1,398 | 14.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 14 | $4,825 | $1,300 | 26.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 21 | $4,817 | $1,277 | 26.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 24 | 76 | $3,830 | $1,239 | 32.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 58 | $5,715 | $1,120 | 19.6% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 22 | 8,700 | $27,927 | $1,042 | 3.7% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 11 | 421 | $2,041 | $776.86 | 38.1% |
About Dr. Nicholas Barber, MD
Dr. Nicholas Barber, MD is a Internal Medicine healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508033465.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Barber, MD has received a total of $838.46 in payments from pharmaceutical and medical device companies, with $233.72 received in 2024. These payments were reported across 42 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($763.56).
As a Medicare-enrolled provider, Barber has provided services to 6,046 Medicare beneficiaries, totaling 183,645 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 151 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location Salem, OR
- Active Since 05/09/2008
- Last Updated 06/30/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508033465
Products in Payments
- Xospata (Drug) $106.00
- LIBTAYO (Biological) $55.39
- Enhertu (Drug) $49.23
- KEYTRUDA (Biological) $48.66
- FOTIVDA (Drug) $48.06
- ELITEK (Biological) $44.82
- IMBRUVICA (Drug) $39.37
- INJECTAFER (Drug) $36.06
- MEKINIST (Drug) $28.28
- REBLOZYL (Biological) $25.56
- DARZALEX (Biological) $23.56
- ZEJULA (Drug) $21.73
- XOSPATA (Drug) $20.10
- Xermelo (Drug) $18.52
- BELEODAQ (Drug) $18.08
- PROMACTA (Drug) $17.92
- clonoSEQ (Device) $17.92
- Onivyde (Drug) $16.23
- KISQALI (Drug) $13.88
- TUKYSA (Drug) $13.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salem
Dr. Michael Katcher, Md, MD
Internal Medicine — Payments: $124,347
Internal Medicine $124,347
Jonh Pineda-Bonilla, Md, MD
Internal Medicine — Payments: $51,042
Internal Medicine $51,042
Dr. Garry Miller, D.o, D.O
Internal Medicine — Payments: $17,070
Internal Medicine $17,070
David Bennion, Md, MD
Internal Medicine — Payments: $13,939
Internal Medicine $13,939
Mr. Gautam Jha, Md, MD
Internal Medicine — Payments: $11,191
Internal Medicine $11,191
Dr. Troy Lunceford, Md, MD
Internal Medicine — Payments: $10,868
Internal Medicine $10,868